Skip to content
HowShorted

RHYTHM PHARMACEUTICALS, INC. short interest in 2022

In 2022, RHYTHM PHARMACEUTICALS, INC.'s disclosed short interest ran from 7.83% of shares outstanding on 14 Jan 2022 to 13.91% on 30 Dec 2022, a change of +6.08 percentage points. The year's high was 16.55% on 31 Oct 2022 and its low 6.15% on 13 May 2022, averaging 10.67% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.69 days on 30 Nov 2022. Full history: RHYTHM PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for RHYTHM PHARMACEUTICALS, INC. in 2022

2022 in figures

Start of year
7.83% (14 Jan 2022)
End of year
13.91% (30 Dec 2022)
Change
+6.08 pp
High
16.55% (31 Oct 2022)
Low
6.15% (13 May 2022)
Average
10.67%
Highest days to cover
15.69 (30 Nov 2022)
SEC filings marked
8

Every report in 2022

RHYTHM PHARMACEUTICALS, INC. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20227.83%12.27
31 Jan 20228.24%11.85
15 Feb 20228.70%6.97
28 Feb 20229.06%4.64
15 Mar 20229.60%10.1310-K filed, results (8-K)
31 Mar 20227.46%5.20
14 Apr 20227.34%10.06
29 Apr 20226.79%14.07
13 May 20226.15%4.8910-Q filed, results (8-K)
31 May 20227.13%6.92
15 Jun 20227.28%5.12
30 Jun 20226.29%1.06
15 Jul 202211.80%1.18
29 Jul 202214.27%1.85
15 Aug 202211.04%2.91results (8-K), 10-Q filed
31 Aug 202211.45%6.84
15 Sep 202211.89%3.37
30 Sep 202215.05%4.46
14 Oct 202215.02%9.19
31 Oct 202216.55%13.94
15 Nov 202214.98%10.6710-Q filed, results (8-K)
30 Nov 202213.96%15.69
15 Dec 202214.35%13.07
30 Dec 202213.91%13.95

See also: RHYTHM PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.